Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03638583 · ClinicalTrials.gov registry record
Alzheimer Prevention Trials (APT) Webstudy
A clinical trial of Alzheimer Disease and Dementia, sponsored by University of Southern California.
- Recruiting
- Registry status
- 200,000
- Enrollment target
- 1
- Study location
NCT03638583: Recruiting study of Alzheimer Disease and Dementia, sponsored by University of Southern California.
NCT03638583 is a study of Alzheimer Disease and Dementia that is actively recruiting participants, run by University of Southern California. The registered enrollment target is 200,000 participants, above the 2,097-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (9437% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03638583, a study of Alzheimer Disease and Dementia, is actively recruiting participants, sponsored by University of Southern California.
- RECRUITING
- Registry status
- 200,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of the Alzheimer Prevention Trials (APT) Webstudy is to accelerate enrollment for Alzheimer's disease (AD) clinical trials by identifying and tracking individuals who may be at higher risk for developing AD dementia.
Conditions Studied
Study Locations (1)
California
- Https://Www.Aptwebstudy.Org - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200,000 participants |
| Start Date | 2017-12-20 |
| Est. Completion | 2026-04-30 |
What NCT03638583 shows while recruiting
NCT03638583 is an observational study that tracks outcomes without assigning an intervention. Its 200,000 participants enrollment target places it among the larger protocols in the corpus, above the 2,097-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (9437% higher).
The record links to 2 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 0 interventions.
NCT03638583 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03638583 about?
NCT03638583 is a clinical study titled "Alzheimer Prevention Trials (APT) Webstudy". The goal of the Alzheimer Prevention Trials (APT) Webstudy is to accelerate enrollment for Alzheimer's disease (AD) clinical trials by identifying and tracking individuals who may be at higher risk for developing AD dementia.
What is the current status of trial NCT03638583?
This trial is currently recruiting. The enrollment target is 200,000 participants. The study started on 2017-12-20. Estimated completion is 2026-04-30.
What conditions does trial NCT03638583 study?
This clinical trial studies the following conditions: Alzheimer Disease, Dementia.
Who is sponsoring clinical trial NCT03638583?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03638583 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03638583's enrollment target sits among peer trials
200,000 2nd of 306 the highest of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06090578 · 180,000 participants · NA
TabCAT Brain Health Assessment in Primary Care
- NCT06917339 · 156,000 participants
Retrospective Analyses of TrakStar Database
- NCT06232551 · 152,000 participants · NA
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
- NCT04735835 · 250,000 participants · NA
Personalized Responses to Dietary Composition Trial 3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI